A program to provide experimental treatments to a class of patients who lack satisfactory alternative treatments. IND stands for Investigational New Drug application, which is part of the process to get approval from the FDA for marketing a new prescription drug in the U.S.
a mechanism used by FDA to make investigational new drugs available to patients while they are under study
a treatment protocol that is added to an existing investigational new drug application (IND)
A program to provide experimental treatment free of charge to patients who have no other available treatment options  Click here to return to list Click here to return to list Click here to return to list
A method by which the FDA allows seriously ill patients with no acceptable therapeutic alternative access to promising Investigational New Drugs. The therapy must show "sufficient evidence of safety and effectiveness."
A mechanism that allows promising investigational drugs to be used in "expanded access" protocols--relatively unrestricted studies in which the intent is both to learn more about the drugs, especially their safety, and to provide treatment for people with immediately life-threatening or otherwise serious diseases for which there is no real alternative. But these expanded access protocols also require researchers to formally investigate the drugs in well-controlled studies and to supply some evidence that the drugs are likely to be helpful. The drugs cannot expose patients to unreasonable risk.
An FDA program that makes experimental drugs available to seriously ill people. Drug companies may charge for the drug, although most don't.
A program to provide experimental treatments to a class of patients who lack satisfactory alternative treatments. IND stands for Investigational New Drug application, which is part of the FDA approval process to market a new prescription drug in the United States.
IND stands for Investigational New Drug application, which is part of the process to get approval from the FDA for marketing a new prescription drug in the U.S. It makes promising new drugs available to desperately ill participants as early in the drug development process as possible. Treatment INDs are made available to participants before general marketing begins, typically during Phase III studies. To be considered for a treatment IND a participant cannot be eligible to be in the definitive clinical trial.
A method through which the FDA allows seriously ill patients with no acceptable therapeutic alternative to access promising investigational drugs still in clinical development. The drug must show "sufficient evidence of safety and effectiveness." In recent decades many AIDs patients have been able to access unapproved therapies through this program.
A provision of the Federal Food, Drug and Cosmetic Act that allows patients with life-threatening or serious diseases to obtain certain drugs that are in late stages of clinical testing, but have not yet been approved by FDA for marketing.
A program to provide experimental treatments to a class of patients lacking satisfactory alternative treatment.
